Literature DB >> 11178961

V3 induces in human normal cell populations an accelerated macrophage-mediated proliferation--apoptosis phenomenon of effector T cells when they respond to their cognate antigen.

A Zafiropoulos1, S Baritaki, M Sioumpara, D A Spandidos, E Krambovitis.   

Abstract

The semi-conserved domain of V3 of HIV-1 was synthesised in a lipopeptide form to be presented on the surface of liposome particles. Composite liposomes were constructed with entrapped tetanus toxoid as a recall antigen (lipo-V3/TT liposomes) to study the influence of V3 on effector T cells of human normal peripheral lymphocyte populations. We demonstrated that lipo-V3/TT liposomes induce a V3-specific response characterised by an early, enhanced proliferation of effector CD4+ T cells, followed by a sharp apoptosis. The phenomenon required the presence of monocyte-derived macrophages and CD4+ T cells, but it was qualitatively and quantitatively distinct from the normal soluble antigen-mediated antigen presenting cell: T cell interaction. Presence of the beta-chemokine RANTES in the culture medium inhibited the phenomenon, suggesting that V3 plays a costimulatory role that involves the chemokine receptor CCR5 pathway during the process of antigen presentation to T cells. This observation may be very important if it occurs also in HIV-1 infection, as it may explain the selective and progressive depletion of non-infected effector CD4+ T cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11178961     DOI: 10.1006/bbrc.2001.4300

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  1 in total

1.  The HIV-1 gp120/V3 modifies the response of uninfected CD4 T cells to antigen presentation: mapping of the specific transcriptional signature.

Authors:  Antigone K Morou; Filippos Porichis; Elias Krambovitis; George Sourvinos; Demetrios A Spandidos; Alexandros Zafiropoulos
Journal:  J Transl Med       Date:  2011-09-24       Impact factor: 5.531

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.